Dr. Reddy's Laboratories (RDY) Competitors $15.08 +0.20 (+1.34%) As of 07/3/2025 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. TAK, ARGX, ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, and QGENShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Insmed Summit Therapeutics Intra-Cellular Therapies Genmab A/S QIAGEN Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do institutionals & insiders hold more shares of RDY or TAK? 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is RDY or TAK more profitable? Dr. Reddy's Laboratories has a net margin of 17.38% compared to Takeda Pharmaceutical's net margin of 2.36%. Dr. Reddy's Laboratories' return on equity of 17.98% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.38% 17.98% 12.24% Takeda Pharmaceutical 2.36%10.64%5.14% Which has more volatility & risk, RDY or TAK? Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Which has better earnings and valuation, RDY or TAK? Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.30$663M$0.6622.85Takeda Pharmaceutical$30.09B1.64$712.33M$0.2270.68 Is RDY or TAK a better dividend stock? Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.5%. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Does the media favor RDY or TAK? In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 2 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.67 beat Dr. Reddy's Laboratories' score of 0.36 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RDY or TAK? Dr. Reddy's Laboratories currently has a consensus target price of $16.95, indicating a potential upside of 12.40%. Given Dr. Reddy's Laboratories' higher probable upside, equities research analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 11 of the 17 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$12.59B$3.94B$5.53B$20.70BDividend Yield0.54%1.16%5.24%3.71%P/E Ratio22.857.5127.5828.11Price / Sales3.3011.19417.2338.32Price / Cash14.606.5736.8922.53Price / Book3.192.698.034.58Net Income$663M-$109.62M$3.18B$986.06M7 Day Performance0.13%3.27%2.91%2.79%1 Month Performance-2.80%6.54%3.72%5.46%1 Year Performance-3.38%32.08%36.04%15.06% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories2.8055 of 5 stars$15.08+1.3%$16.95+12.4%-0.9%$12.59B$3.81B22.8527,811TAKTakeda Pharmaceutical1.2757 of 5 stars$15.46+2.4%N/A+18.6%$48.05B$30.09B9.5649,281ARGXargenex4.3195 of 5 stars$551.22-1.6%$729.93+32.4%+24.8%$34.20B$2.25B93.361,599Analyst ForecastHigh Trading VolumeONCBeOne Medicines3.4332 of 5 stars$242.07+0.4%$320.67+32.5%N/A$26.44B$3.81B0.0011,000Gap UpBNTXBioNTech2.3723 of 5 stars$106.47-0.2%$137.86+29.5%+37.3%$25.65B$2.98B0.006,772Gap DownTEVATeva Pharmaceutical Industries4.1422 of 5 stars$16.76flat$24.13+43.9%+1.4%$19.22B$16.54B6.8736,830INSMInsmed4.1589 of 5 stars$100.64+1.2%$106.80+6.1%+58.9%$18.87B$363.71M0.001,271Positive NewsSMMTSummit Therapeutics2.5346 of 5 stars$21.28+3.3%$35.09+64.9%+253.3%$15.30B$700K0.00110Trending NewsAnalyst ForecastOptions VolumeITCIIntra-Cellular Therapies0.9719 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.5827 of 5 stars$20.66+0.8%$37.60+82.0%-18.8%$13.15B$3.12B14.752,682QGENQIAGEN4.0446 of 5 stars$48.07+0.6%$49.40+2.8%+22.5%$10.62B$1.98B20.665,765Dividend Announcement Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Insmed Alternatives Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives QIAGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
